Co-Diagnostics (CODX), a leading molecular diagnostics company based in Salt Lake City, has announced a groundbreaking joint venture with Arabian Eagle Manufacturing of Saudi Arabia to establish CoMira Diagnostics<\/strong>, a new entity dedicated to advancing molecular diagnostic technology throughout the Middle East and North Africa (MENA) region.<\/p>\n\n\n\n The joint venture will oversee the research, development, manufacturing, and distribution<\/strong> of Co-Dx\u2019s patented PCR platform and diagnostic technologies across Saudi Arabia and 18 neighboring countries. CoMira\u2019s launch aligns with the strategic pillars of Saudi Vision 2030<\/strong>, emphasizing technology localization, healthcare innovation, and industrial diversification.<\/p>\n\n\n\n Co-Diagnostics CEO Dwight Egan<\/strong> expressed enthusiasm for the partnership, highlighting how it expands access to high-quality PCR diagnostics in rapidly growing markets. He emphasized that pursuing regulatory clearance through the Saudi Food & Drug Administration (SFDA)<\/strong> would accelerate regional entry and support the company\u2019s mission to make reliable testing more accessible.<\/p>\n\n\n\n Arabian Eagle CEO Ihssan Rjoob<\/strong> underscored that the collaboration not only advances healthcare technology but also leverages machine learning and AI<\/strong> to optimize manufacturing processes, promoting sustainable growth and health security within the Kingdom.<\/p>\n\n\n\n The partnership mirrors Co-Diagnostics\u2019 successful model in India with CoSara Diagnostics<\/strong>, granting CoMira exclusive licensing rights to manufacture and market Co-Dx\u2019s PCR products, including upcoming infectious disease tests for tuberculosis, HPV, and respiratory illnesses<\/strong>.<\/p>\n\n\n\n By integrating innovation with local expertise, CoMira Diagnostics positions itself as a pivotal player in regional healthcare transformation, reinforcing Saudi Arabia\u2019s role as a hub for medical technology in the MENA region.<\/p>\n\n\n\n